Aardvark Therapeutics has filed for a $100 million IPO on NASDAQ, seeking to advance its Phase III drug candidate ARD-101 for treating hyperphagia in Prader-Willi syndrome.
Aardvark Therapeutics, Inc. has appointed Dr. Roy D. Baynes and Susan E. Graf to its Board of Directors, aiming to bolster its leadership and advance its innovative therapies for metabolic diseases. The company is progressing with its lead product candidate, ARD-101, through Phase 3 development for Prader-Willi Syndrome and planning a Phase 2 trial for hypothalamic obesity.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.